0 108

Cited 1 times in

Validation of a novel molecular RPA classification in glioblastoma (GBM-molRPA) treated with chemoradiation: A multi-institutional collaborative study

DC FieldValueLanguage
dc.contributor.author김세훈-
dc.contributor.author서창옥-
dc.contributor.author장종희-
dc.contributor.author김나리-
dc.date.accessioned2019-01-15T17:02:08Z-
dc.date.available2019-01-15T17:02:08Z-
dc.date.issued2018-
dc.identifier.issn0167-8140-
dc.identifier.urihttps://ir.ymlib.yonsei.ac.kr/handle/22282913/166770-
dc.description.abstractBACKGROUND AND PURPOSE: A novel molecular recursive partitioning analysis classification has recently been reported integrating the MGMT promoter methylation (MGMTmeth) and IDH1 mutation (IDH1mut) status for glioblastoma (GBM-molRPA) patients treated with temozolomide-based chemoradiation. The current study was initiated to validate the model in a multi-institutional study. MATERIALS AND METHODS: Four-hundred seventy-one newly diagnosed GBM patients (validation cohort) were allocated to classes I-III of the previously reported GBM-molRPA model. Of the patients, 15.7%, 56.1%, and 28.2% patients were GBM-molRPA class I, II, and III, respectively. MGMTmeth and IDH1mut were observed in 32.3 and 8.8% of patients, respectively. In the training plus validation cohort of 692 patients, 16.2%, 60.8%, and 23.0% patients were class I, II, and III, respectively. RESULTS: The median follow-up for survivors and the median survival (MS) of patients was 23.3 and 18.4 months, respectively. The MS for GBM-molRPA class I, II, and III was 49.7 (95% CI, 22.8-76.6), 19.2 (95% CI, 16.2-22.1), and 13.8 months (95% CI, 11.8-15.4) (P < .001 for all comparisons) in the validation cohort. In the training plus validation cohort, the MS was 58.5 (95% CI, 40.7-76.3), 21. (95% CI, 18.6-23.3), and 14.3 months (95% CI, 12.5-16.1) (P < .001 for all comparisons) for class I, II, and III, respectively. CONCLUSION: The GBM-molRPA is a valid model. This GBM-molRPA classification can be useful in clinics and guiding patient stratification in future clinical trials.-
dc.description.statementOfResponsibilityrestriction-
dc.languageEnglish-
dc.publisherElsevier Scientific Publishers-
dc.relation.isPartOfRADIOTHERAPY AND ONCOLOGY-
dc.rightsCC BY-NC-ND 2.0 KR-
dc.rightshttps://creativecommons.org/licenses/by-nc-nd/2.0/kr/-
dc.titleValidation of a novel molecular RPA classification in glioblastoma (GBM-molRPA) treated with chemoradiation: A multi-institutional collaborative study-
dc.typeArticle-
dc.contributor.collegeCollege of Medicine (의과대학)-
dc.contributor.departmentDept. of Pathology (병리학교실)-
dc.contributor.googleauthorChan Woo Wee-
dc.contributor.googleauthorIl Han Kim-
dc.contributor.googleauthorChul-Kee Park-
dc.contributor.googleauthorJin Wook Kim-
dc.contributor.googleauthorYun-Sik Dho-
dc.contributor.googleauthorFumiharu Ohka-
dc.contributor.googleauthorKosuke Aoki-
dc.contributor.googleauthorKazuya Motomura-
dc.contributor.googleauthorAtsushi Natsume-
dc.contributor.googleauthorNalee Kim-
dc.contributor.googleauthorChang-Ok Suh-
dc.contributor.googleauthorJong Hee Chang-
dc.contributor.googleauthorSe Hoon Kim-
dc.contributor.googleauthorWon Kyung Cho-
dc.contributor.googleauthorDo Hoon Lim-
dc.contributor.googleauthorDo-Hyun Nam-
dc.contributor.googleauthorJung Won Choi-
dc.contributor.googleauthorIn Ah Kim-
dc.contributor.googleauthorChae-Yong Kim-
dc.contributor.googleauthorYoung-Taek Oh-
dc.contributor.googleauthorOyeon Cho-
dc.contributor.googleauthorWoong-Ki Chung-
dc.contributor.googleauthorSung-Hwan Kim-
dc.contributor.googleauthorEunji Kim-
dc.identifier.doi10.1016/j.radonc.2018.09.001-
dc.contributor.localIdA00610-
dc.contributor.localIdA01919-
dc.contributor.localIdA01919-
dc.contributor.localIdA03470-
dc.contributor.localIdA03470-
dc.relation.journalcodeJ02597-
dc.identifier.eissn1879-0887-
dc.identifier.pmid30236994-
dc.identifier.urlhttps://www.sciencedirect.com/science/article/pii/S0167814018334686-
dc.subject.keywordGlioblastoma-
dc.subject.keywordIDH1-
dc.subject.keywordMGMT-
dc.subject.keywordRecursive partitioning analysis-
dc.subject.keywordValidation-
dc.contributor.alternativeNameKim, Se Hoon-
dc.contributor.affiliatedAuthor김세훈-
dc.contributor.affiliatedAuthor서창옥-
dc.contributor.affiliatedAuthor서창옥-
dc.contributor.affiliatedAuthor장종희-
dc.contributor.affiliatedAuthor장종희-
dc.citation.volume129-
dc.citation.number2-
dc.citation.startPage347-
dc.citation.endPage351-
dc.identifier.bibliographicCitationRADIOTHERAPY AND ONCOLOGY, Vol.129(2) : 347-351, 2018-
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Pathology (병리학교실) > 1. Journal Papers
1. College of Medicine (의과대학) > Dept. of Radiation Oncology (방사선종양학교실) > 1. Journal Papers
1. College of Medicine (의과대학) > Dept. of Neurosurgery (신경외과학교실) > 1. Journal Papers

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.